Abstract

The absorption of L-thyroxine (L-T4) is influenced by several factors, such as patient’s age, drugs interference, absorption kinetics, dietary habits, adherence to therapy. Issues in the L-T4 absorption could be encountered by patients affected by celiac disease, because of drug malabsorption. We enrolled 22 patients with celiac disease and high serum thyrotropin (TSH) levels in treatment with L-T4 in tablet formulation. All subjects switched to a L-T4 liquid formulation, with no change in the dosage. A circulating TSH levels normalisation/reduction has been obtained in all the patients after the switch from L-T4 in tablet formulation to an oral liquid one with the same L-T4 dosage. Nine subjects switched back again to receive L-T4 in tablets (at the same dosage) reporting a worsening of TSH levels, and TSH values fell into the hypothyroid range. In conclusion, malabsorption issues could be overcome through oral L-T4 liquid formulation administration, in this way leading to ameliorate the management of patients affected by celiac disease.

This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).